An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF ...

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

The interplay between sex and serious bacterial infections, including bacteremia and sepsis, is complex and more research is ...

Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...

The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...

The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

The World Health Organization (WHO) has released an update on polio following the March 2025 meeting of the International ...

Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for PHST001, aimed at treating advanced ...

More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...